

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and Kura Oncology

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Assistant Professors Jolanta Grembecka and Tomasz Cierpicki are both employees of the University of Michigan ("University") and partial owners of Kura Oncology ("Kura"). The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Jolanta Grembecka, Ph.D., an Assistant Professor in Pathology, and Tomasz Cierpicki, Ph.D., an Assistant Professor in Pathology, are the partial owners of Kura (the "Company"). The Company wishes to fund a project entitled: "Menin-MLL Inhibitor Program," (ORSP# 15-PAF03132) in the Department of Pathology under the direction of Dr. Cierpicki. The purpose of this project is to investigate and assess the efficacy of new covalent menin-MLL inhibitors.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately three (3) years. The amount of funding support will not exceed Two Million Seven Hundred Sixteen Thousand Five Hundred Eighty-five Dollars (\$2,716,585). Since research projects are often amended, this agreement includes a provision for changes in time, amount, and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.


Impact of the Agreement

The Agreement will support an effort by Drs. Grembecka and Cierpicki to use their expertise and University laboratory, as well as other University resources to advance menin-MLL inhibitors to clinical trials in mixed-lineage leukemia (MLL) patients.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with Kura Oncology.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'S. Jack Hu', written in a cursive style.

S. Jack Hu
Interim Vice President for Research

February 2015